Characteristics of long-term survival in advanced stage ovarian cancer: a nationwide cohort in the Netherlands

IF 0.5 4区 医学 Q4 OBSTETRICS & GYNECOLOGY
L. van Wagensveld, G. Sonke, K. K. Van de Vijver, H. Horlings, R. Kruitwagen, M. van der Aa
{"title":"Characteristics of long-term survival in advanced stage ovarian cancer: a nationwide cohort in the Netherlands","authors":"L. van Wagensveld, G. Sonke, K. K. Van de Vijver, H. Horlings, R. Kruitwagen, M. van der Aa","doi":"10.31083/j.ejgo4301007","DOIUrl":null,"url":null,"abstract":"Objective: Despite optimal treatment with debulking surgery and chemotherapy, the majority of patients with advanced stage epithelial ovarian cancer (EOC) die within five years. Survival beyond eight years is rare and the mechanisms that lead to such favorable outcomes are incompletely understood. We aimed to identify characteristics associated with long-term survival (LTS) in a population-based cohort of patients with advanced stage EOC.Methods: Patients with advanced stage (FIGO IIB-IV) EOC diagnosed between 2008 and 2012 were identified from the Netherlands Cancer Registry. LTS was defined as survival for more than eight years after diagnosis, based on 20% survival within this cohort. Patient, tumor, and treatment characteristics were analyzed using multivariable logistic regression to find predictors for LTS. Results: We identified 2744 eligible patients of whom 571 were long-term survivors (survival longer than eight years). Younger age, lower tumor stage, low-grade histology, FIGO IV based on extra-abdominal lymph node compared to pleural metastasis, primary debulking surgery vs neo-adjuvant chemotherapy followed by interval debulking surgery, residual disease less than one cm or nomacroscopic disease, and ascites less than 100mLwere associated with LTS. Furthermore, less than six chemotherapy cycles compared to six, and carboplatin plus paclitaxel combined with other chemotherapy agents compared to carboplatin plus paclitaxel, were associated with a lower odds of LTS. Conclusion: Characteristics of the tumor, patient and treatment play a substantial role in respect to the prognosis of advanced stage EOC, and can assist in the prediction of LTS.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":" ","pages":""},"PeriodicalIF":0.5000,"publicationDate":"2022-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of gynaecological oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.31083/j.ejgo4301007","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Objective: Despite optimal treatment with debulking surgery and chemotherapy, the majority of patients with advanced stage epithelial ovarian cancer (EOC) die within five years. Survival beyond eight years is rare and the mechanisms that lead to such favorable outcomes are incompletely understood. We aimed to identify characteristics associated with long-term survival (LTS) in a population-based cohort of patients with advanced stage EOC.Methods: Patients with advanced stage (FIGO IIB-IV) EOC diagnosed between 2008 and 2012 were identified from the Netherlands Cancer Registry. LTS was defined as survival for more than eight years after diagnosis, based on 20% survival within this cohort. Patient, tumor, and treatment characteristics were analyzed using multivariable logistic regression to find predictors for LTS. Results: We identified 2744 eligible patients of whom 571 were long-term survivors (survival longer than eight years). Younger age, lower tumor stage, low-grade histology, FIGO IV based on extra-abdominal lymph node compared to pleural metastasis, primary debulking surgery vs neo-adjuvant chemotherapy followed by interval debulking surgery, residual disease less than one cm or nomacroscopic disease, and ascites less than 100mLwere associated with LTS. Furthermore, less than six chemotherapy cycles compared to six, and carboplatin plus paclitaxel combined with other chemotherapy agents compared to carboplatin plus paclitaxel, were associated with a lower odds of LTS. Conclusion: Characteristics of the tumor, patient and treatment play a substantial role in respect to the prognosis of advanced stage EOC, and can assist in the prediction of LTS.
晚期癌症的长期生存特征:荷兰全国性队列研究
目的:尽管减瘤手术和化疗是最佳的治疗方法,但大多数晚期癌症(EOC)患者在五年内死亡。存活超过八年是罕见的,导致这种有利结果的机制尚不完全清楚。我们的目的是在一个以人群为基础的晚期EOC患者队列中确定与长期存活率(LTS)相关的特征。方法:从荷兰癌症登记处确定2008年至2012年诊断的晚期(FIGO IIB-IV)EOC患者。LTS被定义为诊断后存活超过8年,基于该队列中20%的存活率。使用多变量逻辑回归分析患者、肿瘤和治疗特征,以寻找LTS的预测因素。结果:我们确定了2744名符合条件的患者,其中571人为长期幸存者(存活时间超过8年)。年龄较小、肿瘤分期较低、组织学分级较低、与胸膜转移相比基于腹外淋巴结的FIGO IV、初次减瘤手术与新辅助化疗后间隔减瘤手术、小于1cm的残余疾病或肉眼可见的疾病以及小于100mL的腹水与LTS相关。此外,与6个化疗周期相比,少于6个化疗循环,与卡铂加紫杉醇相比,卡铂加紫醇与其他化疗药物联合使用,与LTS的几率较低有关。结论:肿瘤的特点、患者和治疗对晚期EOC的预后有重要影响,有助于预测LTS。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
25.00%
发文量
58
审稿时长
1 months
期刊介绍: EJGO is dedicated to publishing editorial articles in the Distinguished Expert Series and original research papers, case reports, letters to the Editor, book reviews, and newsletters. The Journal was founded in 1980 the second gynaecologic oncology hyperspecialization Journal in the world. Its aim is the diffusion of scientific, clinical and practical progress, and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists, and so on.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信